Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients

Cancer Immunology Immunotherapy

Volumn 48, Issue 8, 1999, Pages 435-442

  Goto, Shigenori ^a   Sato, Manami ^a   Kaneko, Ryuta ^a   Itoh, Masayoshi ^a   Sato, Shinobu ^b   Takeuchi, Shoshichi ^a  

^a Institute of Bioregulation   (Japan)

^b Yokohama Sato Clinic   (Japan)

Author keywords

Cytokines; IFN ; IL 2; Immunotherapy; Th1 and Th2

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MALE; MELANOMA; MONONUCLEAR PHAGOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; STOMACH CANCER; T LYMPHOCYTE SUBPOPULATION; TREATMENT PLANNING;

ADULT; AGED; CYTOKINES; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASMS; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032740961     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050620     Document Type: Article

References (35)

1. Bloom BR, Salgame P, Diamond B (1992) Revisiting and revising suppressor T cells. Immunol Today 13:131
2. Case DC, Hansen JA, Corrsles E, Young CW, Dupont B, Pinsky CM, Good RA (1976) Comparison of multiple in vivo and in vitro parameters in untreated patients with Hodgkin's disease. Cancer 38:1807
3. D'Andrea A, Aste-Amezaga, Valiante NM, Ma X, Kubin M, Trinchieri G (1993) Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178:1041
4. Del Prete GF, De Carli M, Ricci M, Romagnani S (1991) Helper activity for immunoglobulin synthesis of T helper type 1 (Th1) and Th2 human T cell clones: the help of Th1 clones is limited by their cytolytic capacity. J Exp Med 174:809
5. Golub SH, Rangel DM, Morton DL (1977) In vitro assessment of immunocompetence in patients with malignant melanoma. Int J Cancer 20:873
6. Goto S, Sakai S, Kera J, Suma Y, Soma G-I, Takeuchi S (1994) Case report of recurrent cervical cancer which responded to a combination of biological therapies. Eur J Gynecol Oncol 15:235
7. Goto S, Sakai S, Kera J, Suma Y, Soma G-I, Takeuchi S (1996) Intradermal administration of lipopolysaccharide in treatment of human cancer. Cancer Immunol Immunother 42:255
8. Hernandez-Pando R, Rook GAW (1994) The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 82:591
9. Jung T, Lack G, Schauer U, Uberruck W, Renz H, Gelfand EW (1995) Allergens. IgE, mediators, inflammatory mechanisms. Decreased frequency of interferera γ and interleukin-2-producing cells in patients with atopic diseases measured at the single cell level. J Allergy Clin Immunol 96:515
10. Karadovin LM, Giuliano AE, Golub SH (1981) T lymphocyte subsets in patients with malignant melanoma. Cancer Immunol Immunother 11:251
11. Kavanaugh DY, Carbone DP (1996) Immunologic dysfunction in cancer. Hematol Oncol Clin North Am 10:927
12. Lee ET, Ishmael R, Bottomley RH, Murray JL (1982) An analysis of skin tests and their relationship to recurrence and survival in stage III and stage IV melanoma patients. Cancer 49:2336
13. Liu YK, Grimaldi M, Dannaher CL (1978) Myelopoietic abnormalities in patients with metastatic cancer. Cancer 41:1193
14. Lucey DR, Clerici M, Shearer GM (1996) Type 1 and type 2 cytokine dysregulation in human infections, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9:532
15. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trichieri G, Romagnani S (1993) Natural killer cell stimulatory factor (Interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177:1199
16. Manson LA (1991) Does antibody-dependent epitope masking permit progressive tumour growth in the face of cell-mediated cytotoxicity? Immunol Today 12:352
17. McHugh S, Deighton J, Rifkin I, Ewan P (1996) Kinetics and functional implications of Th1 and Th2 cytokine production following activation of peripheral blood mononuclear cells in primary culture. Eur J Immunol 26:1260
18. Meyaard L, Hovenkamp E, Keet IPM, Hooibrink B, Jong IH, Otto SA, Miedema F (1996) Single-cell analysis of IL-4 and IFNγ production by T cells from HIV-infected individuals. J Immunol 157:2712
19. Mosmann TR, Coffman RL (1989) Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145
20. Old LJ (1987) Tumor necrosis factor. Polypeptide mediator network. Nature 326:330
21. + T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42:1
22. Picker LJ, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, Bergstresser PR, Maino VC (1995) Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 86:1408
23. + cytotoxic T lymphocyte-mediated lysis. J Immunol 150:4303
24. Romagnani S, Del Prete GF, Maggi E, Bosi A, Bernardi F, Ponticelli P, Di Lollo S, Ricci M (1983) Displacement of T lymphocytes with the "helper/inducer" phenotype from peripheral blood to lymphoid organs in untreated patients with Hodgkin's disease. Scand J Haematol 31:305
25. Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP (1996) Predominance of a type 2 intratumoral immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol 105:344
26. Saltz J, Buckley CE, Cox E, Seigler HF (1987) The prognostic significance of recall antigen testing in melanoma patients. Am J Med Sci 294:287
27. + T cells. Annu Rev Immunol 12:635
28. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM (1985) Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transfected cells in vitro. Science 230:943
29. Tripp CS, Wolf SF, Unanue ER (1993) Interleukin 12 and tumor necrosis factor α are costimulators of Interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin-10 is a physiologic antagonist. Proc Natl Acad Sci USA 90:3725
30. Twomey JJ, Rice L (1980) Impact of Hodgkin's disease upon the immune system. Semin Oncol 7:114
31. Vose BM, Gallagher P, Moore M, Schofield PF (1981) Specific and nonspecific lymphocyte cytotoxicity in colon carcinoma. Br J Cancer 44:846
32. Wanidworanum C, Stober W (1993) Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 151:6853
33. + cytotoxic T lymphocytes. J Immunol 143:1518
34. + T cell clones and peripheral blood T cells. J Immunol 149:2378
35. Zielinski CC, Mueller C, Tyl E, Tichatschek E, Kubista E, Spona J (1990) Impaired production of tumor necrosis factor in breast cancer. Cancer 66:1944